Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.
Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P; BMBF Competence Network "Inflammatory Bowel disease". Schreiber S, et al. Among authors: lofberg r. Int J Colorectal Dis. 2001 Feb;16(1):1-11; discussion 12-3. doi: 10.1007/s003840100285. Int J Colorectal Dis. 2001. PMID: 11317691
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Sandborn WJ, et al. Among authors: lofberg r. Am J Gastroenterol. 2005 Aug;100(8):1780-7. doi: 10.1111/j.1572-0241.2005.41992.x. Am J Gastroenterol. 2005. PMID: 16086715 Clinical Trial.
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. D'Haens GR, et al. Among authors: lofberg r. Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2. Am J Gastroenterol. 2011. PMID: 21045814 Review.
Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.
Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Muratov V, et al. Among authors: lofberg r. Int J Colorectal Dis. 2006 Sep;21(6):493-504. doi: 10.1007/s00384-005-0069-2. Epub 2006 Mar 15. Int J Colorectal Dis. 2006. PMID: 16538495
A comparison of budesonide with prednisolone for active Crohn's disease.
Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H, et al. Rutgeerts P, et al. Among authors: lofberg r. N Engl J Med. 1994 Sep 29;331(13):842-5. doi: 10.1056/NEJM199409293311304. N Engl J Med. 1994. PMID: 8078530 Free article. Clinical Trial.
Identification of a new WASP and FKBP-like (WAFL) protein in inflammatory bowel disease: a potential marker gene for ulcerative colitis.
Viklund IM, Kuznetsov NV, Löfberg R, Daperno M, Sostegni R, Astegiano M, Rizzetto M, von Stein O, D'Amato M, von Stein P, Pettersson S. Viklund IM, et al. Among authors: lofberg r. Int J Colorectal Dis. 2008 Oct;23(10):921-30. doi: 10.1007/s00384-008-0527-8. Epub 2008 Jul 25. Int J Colorectal Dis. 2008. PMID: 18654788
137 results